Skip to content

Nasdaq · CIK 0001235912

CVRX CVRx, Inc.

Insider trading from SEC Form 4. Last filing Mar 16, 2026. Close $1.58 on Oct 9, 2026, +3% from the 52-week low and -85% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company

Price and insider trades, last year

CVRXOct 9, 2026 · close 1.58

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at CVRx, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
10WeakPhilip B. Adamson
Chief Medical Officer
sell
$9,973
1,262 shares
-2%+73% from low-37% from high
27WeakKevin Hykes
PRES & CEO
sell
$61k
7,763 shares
-3%+73% from low-37% from high
17WeakJared Oasheim
CHIEF FINANCIAL OFFICER
sell
$14k
1,744 shares
-2%+73% from low-37% from high
10WeakPaul Verrastro
CHIEF MKTG & STRAT OFFICER
sell
$10k
1,284 shares
-2%+73% from low-37% from high
15WeakRobert Allen John
Chief Revenue Officer
sell
$31k
3,964 shares
-4%+73% from low-37% from high
45ModerateMudit K. Jain
director
buy
$298k
46,800 shares
+5%+29% from low-56% from high
36WeakMudit K. Jain
director
buy
$2,785
600 shares
+12%+2% from low-68% from high
20WeakJohnson & Johnson
owner
sell
$64k
6,337 shares
-0%+107% from low-47% from high
17WeakJohnson & Johnson
owner
sell
$27k
2,700 shares
-0%+107% from low-46% from high
12WeakJohnson & Johnson
owner
sell
$10k
1,000 shares
-0%+100% from low-48% from high
31WeakJohnson & Johnson
owner
sell
$536k
52,532 shares
-1%+112% from low-45% from high
45ModerateKirk G. Nielsen
director
buy
$60k
10,966 shares
+1%+30% from low-66% from high
76NotableKirk G. Nielsen
director
buy
$977k
187,813 shares
+11%0% from low-74% from high
54ModerateMudit K. Jain
director
buy
$7,775
1,650 shares
+49%0% from low-74% from high
58ModerateKevin Hykes
PRES & CEO
buy
$24k
5,000 shares
+4%0% from low-74% from high
10WeakPaul Verrastro
CHIEF MKTG & STRAT OFFICER
sell
$19k
1,430 shares
-43%-

Transactions

The last 56 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Feb 27, 2026Philip B. Adamson
Chief Medical Officer
AGrant or award
Common Stock10b5-1
+41,000$0.00$062,840Mar 16, 2026
Mar 2, 2026Philip B. Adamson
Chief Medical Officer
SOpen-market sale
Common Stock10b5-1
-1,262$7.90$9,97361,578Mar 16, 2026
Feb 27, 2026Philip B. Adamson
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative10b5-1
+62,000$0.00$062,000Mar 16, 2026
Mar 2, 2026Gregory Morrison
CHIEF HUMAN RESOURCES OFFICER
AGrant or award
Common Stock
+34,000$0.00$034,000Mar 4, 2026
Mar 2, 2026Gregory Morrison
CHIEF HUMAN RESOURCES OFFICER
AGrant or award
Stock Option (right to buy)derivative
+154,500$0.00$0154,500Mar 4, 2026
Feb 27, 2026Robert Allen John
Chief Revenue Officer
AGrant or award
Common Stock10b5-1
+35,000$0.00$090,000Mar 3, 2026
Feb 27, 2026Paul Verrastro
CHIEF MKTG & STRAT OFFICER
AGrant or award
Common Stock10b5-1
+45,000$0.00$061,835Mar 3, 2026
Feb 27, 2026Jared Oasheim
CHIEF FINANCIAL OFFICER
AGrant or award
Common Stock10b5-1
+61,000$0.00$098,447Mar 3, 2026
Feb 27, 2026Brent Binkowski
CHIEF OPERATING OFFICER
AGrant or award
Common Stock
+15,000$0.00$031,600Mar 3, 2026
Feb 27, 2026Kevin Hykes
PRES & CEO
AGrant or award
Common Stock10b5-1
+159,000$0.00$0292,000Mar 3, 2026
Mar 2, 2026Kevin Hykes
PRES & CEO
SOpen-market sale
Common Stock10b5-1
-7,763$7.90$61k284,237Mar 3, 2026
Mar 2, 2026Robert Allen John
Chief Revenue Officer
SOpen-market sale
Common Stock10b5-1
-3,964$7.90$31k86,036Mar 3, 2026
Mar 2, 2026Paul Verrastro
CHIEF MKTG & STRAT OFFICER
SOpen-market sale
Common Stock10b5-1
-1,284$7.90$10k60,551Mar 3, 2026
Mar 2, 2026Jared Oasheim
CHIEF FINANCIAL OFFICER
SOpen-market sale
Common Stock10b5-1
-1,744$7.90$14k96,703Mar 3, 2026
Feb 27, 2026Brent Binkowski
CHIEF OPERATING OFFICER
AGrant or award
Stock Option (right to buy)derivative
+23,000$0.00$023,000Mar 3, 2026
Feb 27, 2026Kevin Hykes
PRES & CEO
AGrant or award
Stock Option (right to buy)derivative10b5-1
+238,000$0.00$0238,000Mar 3, 2026
Feb 27, 2026Jared Oasheim
CHIEF FINANCIAL OFFICER
AGrant or award
Stock Option (right to buy)derivative10b5-1
+91,000$0.00$091,000Mar 3, 2026
Feb 27, 2026Paul Verrastro
CHIEF MKTG & STRAT OFFICER
AGrant or award
Stock Option (right to buy)derivative10b5-1
+67,000$0.00$067,000Mar 3, 2026
Feb 27, 2026Robert Allen John
Chief Revenue Officer
AGrant or award
Stock Option (right to buy)derivative10b5-1
+52,000$0.00$052,000Mar 3, 2026
Feb 20, 2026Mudit K. Jain
director
POpen-market purchase
Common Stockindirect: See footnote
+46,800$6.36$298k980,183Feb 23, 2026
Feb 18, 2026Mudit K. Jain
director
POpen-market purchase
Common Stock
+600$4.64$2,7855,650Feb 18, 2026
Nov 26, 2025Johnson & Johnson
owner
SOpen-market sale
Common Stockindirect: By Johnson & Johnson Innovation - JJDC, Inc.
-6,337$10.03$64k4,040,861Dec 1, 2025
Nov 21, 2025Johnson & Johnson
owner
SOpen-market sale
Common Stockindirect: By Johnson & Johnson Innovation - JJDC, Inc.
-500$10.00$5,0004,049,398Nov 25, 2025
Nov 24, 2025Johnson & Johnson
owner
SOpen-market sale
Common Stockindirect: By Johnson & Johnson Innovation - JJDC, Inc.
-2,200$10.06$22k4,047,198Nov 25, 2025
Nov 12, 2025Johnson & Johnson
owner
SOpen-market sale
Common Stockindirect: By Johnson & Johnson Innovation - JJDC, Inc.
-1,000$10.00$10k4,049,898Nov 14, 2025
Nov 6, 2025Johnson & Johnson
owner
SOpen-market sale
Common Stockindirect: By Johnson & Johnson Innovation - JJDC, Inc.
-52,332$10.21$534k4,051,098Nov 10, 2025
Nov 7, 2025Johnson & Johnson
owner
SOpen-market sale
Common Stockindirect: By Johnson & Johnson Innovation - JJDC, Inc.
-200$10.00$2,0004,050,898Nov 10, 2025
Aug 11, 2025Brent Binkowski
CHIEF OPERATING OFFICER
AGrant or award
Common Stock
+16,600$0.00$016,600Aug 13, 2025
Aug 11, 2025Brent Binkowski
CHIEF OPERATING OFFICER
AGrant or award
Stock Option (right to buy)derivative
+74,900$0.00$074,900Aug 13, 2025
Jun 3, 2025Martha Shadan
director
AGrant or award
Stock Option (right to buy)derivative
+19,554$0.00$019,554Jun 5, 2025
Jun 3, 2025Mitch C. Hill
director
AGrant or award
Stock Option (right to buy)derivative
+19,554$0.00$019,554Jun 5, 2025
Jun 3, 2025Joseph P Slattery
director
AGrant or award
Stock Option (right to buy)derivative
+19,554$0.00$019,554Jun 5, 2025
Jun 3, 2025Mudit K. Jain
director
AGrant or award
Stock Option (right to buy)derivative
+19,554$0.00$019,554Jun 5, 2025
Jun 3, 2025Kirk G. Nielsen
director
AGrant or award
Stock Option (right to buy)derivative
+19,554$0.00$019,554Jun 5, 2025
Jun 3, 2025Kevin J. Ballinger
director
AGrant or award
Stock Option (right to buy)derivative
+19,554$0.00$019,554Jun 5, 2025
May 15, 2025Kirk G. Nielsen
director
POpen-market purchase
Common Stockindirect: See Footnote
+10,966$5.45$60k1,910,134May 19, 2025
May 12, 2025Kirk G. Nielsen
director
POpen-market purchase
Common Stockindirect: See Footnote
+25,200$4.79$121k1,736,555May 14, 2025
May 13, 2025Kirk G. Nielsen
director
POpen-market purchase
Common Stockindirect: See Footnote
+101,413$5.29$536k1,837,968May 14, 2025
May 14, 2025Kirk G. Nielsen
director
POpen-market purchase
Common Stockindirect: See Footnote
+61,200$5.23$320k1,899,168May 14, 2025
May 12, 2025Mudit K. Jain
director
POpen-market purchase
Common Stock
+1,500$4.66$6,9864,900May 13, 2025
May 13, 2025Mudit K. Jain
director
POpen-market purchase
Common Stock
+150$5.26$7895,050May 13, 2025
May 12, 2025Kevin Hykes
PRES & CEO
POpen-market purchase
Common Stock
+5,000$4.84$24k133,000May 12, 2025
Feb 28, 2025Philip B. Adamson
Chief Medical Officer
AGrant or award
Common Stock
+20,000$0.00$020,000Mar 4, 2025
Feb 28, 2025Kevin Hykes
PRES & CEO
AGrant or award
Common Stock
+98,000$0.00$0128,000Mar 4, 2025
Feb 28, 2025Robert Allen John
Chief Revenue Officer
AGrant or award
Common Stock
+55,000$0.00$055,000Mar 4, 2025
Feb 28, 2025Jared Oasheim
CHIEF FINANCIAL OFFICER
AGrant or award
Common Stock
+22,000$0.00$037,447Mar 4, 2025
Feb 28, 2025Paul Verrastro
CHIEF MKTG & STRAT OFFICER
AGrant or award
Common Stock
+16,000$0.00$016,835Mar 4, 2025
Feb 28, 2025Paul Verrastro
CHIEF MKTG & STRAT OFFICER
AGrant or award
Stock Option (right to buy)derivative
+24,000$0.00$024,000Mar 4, 2025
Feb 28, 2025Jared Oasheim
CHIEF FINANCIAL OFFICER
AGrant or award
Stock Option (right to buy)derivative
+33,000$0.00$033,000Mar 4, 2025
Feb 28, 2025Robert Allen John
Chief Revenue Officer
AGrant or award
Stock Option (right to buy)derivative
+38,000$0.00$038,000Mar 4, 2025
Feb 28, 2025Philip B. Adamson
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+30,000$0.00$030,000Mar 4, 2025
Feb 28, 2025Kevin Hykes
PRES & CEO
AGrant or award
Stock Option (right to buy)derivative
+148,000$0.00$0148,000Mar 4, 2025
Nov 19, 2024Paul Verrastro
CHIEF MKTG & STRAT OFFICER
MOption exercise
Common Stock
+2,500$5.14$13k3,305Nov 21, 2024
Nov 19, 2024Paul Verrastro
CHIEF MKTG & STRAT OFFICER
SOpen-market sale
Common Stock
-1,430$13.58$19k1,875Nov 21, 2024
Nov 21, 2024Paul Verrastro
CHIEF MKTG & STRAT OFFICER
GGift
Common Stock
-1,040$0.00$0835Nov 21, 2024
Nov 19, 2024Paul Verrastro
CHIEF MKTG & STRAT OFFICER
MOption exercise
Stock Option (right to buy)derivative
-2,500$0.00$073,306Nov 21, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

CVRX insider trading: CVRx, Inc. | InsiderTell